Literature DB >> 22582881

Accumulation of a repulsive axonal guidance molecule RGMa in amyloid plaques: a possible hallmark of regenerative failure in Alzheimer's disease brains.

J Satoh1, H Tabunoki1, T Ishida1, Y Saito1, K Arima1.   

Abstract

AIMS: RGMa is a repulsive guidance molecule that induces the collapse of axonal growth cones by interacting with the receptor neogenin in the central nervous system during development. It remains unknown whether RGMa plays a role in the neurodegenerative process of Alzheimer's disease (AD). We hypothesize that RGMa, if it is concentrated on amyloid plaques, might contribute to a regenerative failure of degenerating axons in AD brains.
METHODS: By immunohistochemistry, we studied RGMa and neogenin (NEO1) expression in the frontal cortex and the hippocampus of 6 AD and 12 control cases. The levels of RGMa expression were determined by qRT-PCR and Western blot in cultured human astrocytes following exposure to cytokines and amyloid beta (Aβ) peptides.
RESULTS: In AD brains, an intense RGMa immunoreactivity was identified on amyloid plaques and in the glial scar. In the control brains, the glial scar and vascular foot processes of astrocytes expressed RGMa immunoreactivity, while oligodendrocytes and microglia were negative for RGMa. In AD brains, a small subset of amyloid plaques expressed a weak NEO1 immunoreactivity, while some reactive astrocytes in both AD and control brains showed an intense NEO1 immunoreactivity. In human astrocytes, transforming growth factor beta-1 (TGFβ1 ), Aβ 1-40 or Aβ 1-42 markedly elevated the levels of RGMa, and TGFβ1 also increased its own levels. Coimmunoprecipitation analysis validated the molecular interaction between RGMa and the C-terminal fragment β of amyloid beta precursor protein (APP). Furthermore, recombinant RGMa protein interacted with amyloid plaques in situ.
CONCLUSIONS: RGMa, produced by TGFβ-activated astrocytes and accumulated in amyloid plaques and the glial scar, could contribute to the regenerative failure of degenerating axons in AD brains.
© 2012 The Authors. Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society.

Entities:  

Keywords:  Alzheimer's disease; RGMa; TGFbeta; astrocytes; neogenin

Mesh:

Substances:

Year:  2013        PMID: 22582881     DOI: 10.1111/j.1365-2990.2012.01281.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  18 in total

1.  Finding New Ways How to Control BACE1.

Authors:  Jarmila Nahálková
Journal:  J Membr Biol       Date:  2022-03-19       Impact factor: 1.843

2.  Effective neuroprotection by ischemic postconditioning is associated with a decreased expression of RGMa and inflammation mediators in ischemic rats.

Authors:  Yuhan Kong; Mary R Rogers; Xinyue Qin
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

3.  Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients.

Authors:  Thomas Müller; Stefan Barghorn; Sven Lütge; Thomas Haas; Reinhold Mueller; Bjoern Gerlach; Gabi Öhm; Katrin Eilert; Isabel Trommer; Bernhard K Mueller
Journal:  J Neural Transm (Vienna)       Date:  2014-09-11       Impact factor: 3.575

4.  Lentiviral Vector-Induced Overexpression of RGMa in the Hippocampus Suppresses Seizures and Mossy Fiber Sprouting.

Authors:  Ling Chen; Baobing Gao; Min Fang; Jie Li; Xiujuan Mi; Xin Xu; Wei Wang; Juan Gu; Bo Tang; Yanke Zhang; Zhihua Wang; Ao Zhan; Guojun Chen; Xuefeng Wang
Journal:  Mol Neurobiol       Date:  2016-02-03       Impact factor: 5.590

5.  Genome-wide Association Study Identifies a Regulatory Variant of RGMA Associated With Opioid Dependence in European Americans.

Authors:  Zhongshan Cheng; Hang Zhou; Richard Sherva; Lindsay A Farrer; Henry R Kranzler; Joel Gelernter
Journal:  Biol Psychiatry       Date:  2018-01-11       Impact factor: 13.382

6.  RGMa can induce skeletal muscle cell hyperplasia via association with neogenin signalling pathway.

Authors:  Alinne do Carmo Costa; Aline Gonçalves Lio Copola; Clara Carvalho E Souza; Júlia Meireles Nogueira; Gerluza Aparecida Borges Silva; Erika Cristina Jorge
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-03-21       Impact factor: 2.416

Review 7.  Perspective: Treatment for Disease Modification in Chronic Neurodegeneration.

Authors:  Thomas Müller; Bernhard Klaus Mueller; Peter Riederer
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

Review 8.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

9.  A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex.

Authors:  Rebecca G Smith; Ehsan Pishva; Gemma Shireby; Adam R Smith; Janou A Y Roubroeks; Eilis Hannon; Gregory Wheildon; Diego Mastroeni; Gilles Gasparoni; Matthias Riemenschneider; Armin Giese; Andrew J Sharp; Leonard Schalkwyk; Vahram Haroutunian; Wolfgang Viechtbauer; Daniel L A van den Hove; Michael Weedon; Danielle Brokaw; Paul T Francis; Alan J Thomas; Seth Love; Kevin Morgan; Jörn Walter; Paul D Coleman; David A Bennett; Philip L De Jager; Jonathan Mill; Katie Lunnon
Journal:  Nat Commun       Date:  2021-06-10       Impact factor: 14.919

Review 10.  View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson's Disease: Are We on the Right Track?

Authors:  Thomas Müller
Journal:  Biologics       Date:  2021-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.